SCHEMBL1738490

SCHEMBL1738490

CC(=O)c1ccccc1S

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.70
HDAC8 Q9BY41 1/20 0.70
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA5A P35218 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 3/20 0.41
MDM4 O15151 1/20 0.41
TP53 P04637 1/20 0.41
PBRM1 Q86U86 1/20 0.41
MEN1 O00255 1/20 0.41
NSD2 O96028 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29786245 1.00 MAPT (0.70) MAPTHDAC8CA12CA1CA2
Water SCHEMBL28883133 0.98 MAPT (0.67) MAPTHDAC8CA12CA1CA2
SCHEMBL28195614 0.98 MAPT (0.67) MAPTHDAC8CA12CA1CA2
SCHEMBL28855210 0.98 MAPT (0.67) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL28933918 0.83 MAPT (0.91) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL3073817 0.83 MAPT (0.91) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL31208541 0.82 MAPT (1.00) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL28313023 0.82 MAPT (1.00) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL629705 0.82 MAPT (1.00) MAPTHDAC8CA12CA1CA2
Thiosalicylic Acid SCHEMBL50376 0.82 MAPT (1.00) MAPTHDAC8CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
CN-114956933-A Marker containing isotope oxygen atom and preparation method and application thereof 清华大学 2022-08-30 CN disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 CN disclosed
WO-2022111202-A1 3,5-DIMETHYL-4-SULFONE GROUP-1H-PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 中国药科大学 2022-06-02 WO disclosed
CN-109554122-B Curing adhesive for polarizing film, optical film, and image display device 日东电工株式会社 2022-03-01 CN disclosed
CN-109536046-B Curing adhesive for polarizing film, optical film, and image display device 日东电工株式会社 2021-06-11 CN disclosed
US-5296579-A From (hydro)sulfide, polyhalogenated aromatic compound and a mercaptan PHILLIPS PETROLEUM COMPANY (US) 1994-03-22 US disclosed
US-5240826-A Containing a heterocyclic mercapto compound FUJI PHOTO FILM CO., LTD. (JP) 1993-08-31 US disclosed
EP-0230379-B1 CHROMAN- AND THIOCHROMAN-4-ACETIC ACIDS USEFUL IN THE TREATMENT OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1991-04-03 EP disclosed
US-4853410-A Hydroxyacetic acid derivatives for the treatment of diabetic complications PFIZER INC. (US) 1989-08-01 US disclosed
WO-1987004344-A1 HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1987-07-30 WO disclosed
EP-0230379-A2 Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications PFIZER INC. (US) 1987-07-29 EP disclosed
EP-0025528-B1 1-(2-ACETYLPHENYLTHIO)-3-ALKYLAMINO-2-PROPANOLS AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1982-12-29 EP disclosed
EP-0025528-A1 1-(2-Acetylphenylthio)-3-alkylamino-2-propanols and their acid-addition salts, process for their preparation and medicines containing them A. Nattermann & Cie. GmbH (DE) 1981-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 MAPT 1332/4885HDAC8 468/4885CA12 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.